An interventional study of VIA Disc NP and Sham Injection in Degenerative Disc Disease, Disc Degeneration and Lumbar Discogenic Pain, sponsored by VIVEX Biologics, Inc.. Active, not recruiting at 5 sites in Australia. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by VIVEX Biologics, Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Intervertebral Disc Degeneration with a site in Australia — 4 open to participants now, 5 under way, none of them phase 3. Intervertebral Disc Degeneration · Australia.
Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 with no phase, and was the 12th registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →4 of the 13 studies in Intervertebral Disc Degeneration with a site in Australia are open now. Recruiting first, the newest first:
Zetagen Therapeutics, Inc · Sites in Australia
Ages 22–75 · Healthy volunteers
Locate Bio Pty Ltd · Sites in Australia, United States
Ages 22–80
Bone Biologics Corp · Sites in Australia
Ages 17–70
Cartago Biotech Pty Ltd · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 22 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2024.
This study's enrollment of 121 is above the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.
Median enrollment 60 across the 12 interventional studies, 234 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 10 most frequent:
VIVEX Biologics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
VIVEX Biologics, Inc. has 5 studies filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Intervertebral Disc Degeneration with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03810573Bone Biologics CorpEvaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs.
The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.
Participants who consent to participate in the study and meet all eligibility criteria during the Screening/Baseline period will return on Day 1 to be randomized to either the VIA Disc NP or sham-control group. At 12-weeks post-treatment, participants allocated to the sham-control group will be given the option to crossover to the VIA Disc NP group if they meet the requirement to crossover.
All participants will be followed through 52-weeks post-treatment at which time they will be asked if they would like to consent to participate in an extended long-term follow-up period. The sham-control group participants who did not crossover at 12-weeks will be exited from the study at this visit. If participants consent to participate in the extended long-term follow-up period, the VIA Disc NP group will be followed through 24-Months and the sham-control group will be followed through 27-months. If the participant declines participation, they will be exited from the study at this visit.
Key Inclusion Criteria:
Key Exclusion Criteria:
Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study. Pregnancy is confirmed by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: VIA Disc NP
Other: Sham Injection
Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).
Participants will receive the sham procedure at 1 or 2 levels. The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc.
Primary Effectiveness Endpoint - Proportion of participants achieving MCID in VAS score from Baseline to 26 weeks.
A comparison of the proportion of participants who show a minimally clinically important difference (MCID), defined as at least a 30% reduction in back pain VAS score from baseline to 26 weeks (6 months), in the VIA Disc NP group to that in the sham-control group.
Time frame: Baseline to 26 Weeks
Primary Safety Endpoint - Proportion of participants reporting Treatment-related AEs at 12 weeks
The proportion of participants that experience one or more treatment-related (including procedure) adverse events in the VIA Disc NP group compared to the sham-control group at 12 weeks (3 months) as determined by the Principal Investigator.
Time frame: Baseline to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Feb 2026, 16 months.
Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's 16 months is below that.
Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intervertebral Disc Degeneration →
VIVEX Biologics, Inc.